Jefferies Financial Group Weighs in on Swedish Orphan Biovitrum AB (publ)’s Q3 2022 Earnings (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF – Get Rating) – Jefferies Financial Group lifted their Q3 2022 EPS estimates for Swedish Orphan Biovitrum AB (publ) in a research report issued to clients and investors on Wednesday, June 15th. Jefferies Financial Group analyst E. Yang now anticipates that the company will earn $0.11 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Swedish Orphan Biovitrum AB (publ)’s current full-year earnings is $0.81 per share. Jefferies Financial Group also issued estimates for Swedish Orphan Biovitrum AB (publ)’s FY2022 earnings at $0.79 EPS, FY2024 earnings at $1.50 EPS, FY2025 earnings at $1.97 EPS and FY2026 earnings at $1.81 EPS.

Several other analysts also recently issued reports on the stock. DNB Markets raised shares of Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “buy” rating in a report on Thursday, April 14th. Barclays upped their price target on shares of Swedish Orphan Biovitrum AB (publ) from SEK 210 to SEK 215 in a report on Tuesday, February 22nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $215.00.

Shares of BIOVF opened at $20.51 on Friday. Swedish Orphan Biovitrum AB has a twelve month low of $17.00 and a twelve month high of $28.88. The firm has a market capitalization of $6.15 billion, a P/E ratio of 20.36 and a beta of 0.48. The company has a current ratio of 0.93, a quick ratio of 0.53 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average is $21.80 and its two-hundred day moving average is $21.04.

Swedish Orphan Biovitrum AB (publ) Company Profile (Get Rating)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

Further Reading

• Get a free copy of the StockNews.com research report on Swedish Orphan Biovitrum AB (publ) (BIOVF)
• Vuzix Stock Stays Optimistic
• Palo Alto Networks: Pioneering AI in Cybersecurity
• The Analysts Upgrade… Retail Stocks? 
• Dividend Stocks and Your Roth IRA
• The Q2 Earnings Season Could Be A Bloodbath 

Want More Great Investing Ideas?